1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow WetAMD: new trials by email Literature Review of WetAMD trials Research Report on WetAMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
Choroidal Neovascularization (1) · Eye Diseases (1) · Macular Degeneration (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
Choroid Diseases (1) · Eye Diseases, Hereditary (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Uveal Diseases (1)
aflibercept (1)
AbbVie (1)
Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1) · United States (1)